July 26, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it is presenting at the 1
st Annual Sickle Cell Disease Therapeutics Conference. The conference is intended to serve as a forum to raise awareness for sickle cell disease and will include presentations from leading companies in sickle cell disease and discussions with experts regarding the latest advancements and future trends for patients. The conference will be held
September 19, 2012 in the Cosmopolitan Suite at the Four Seasons Hotel in
New York City. Conference sponsors include
Theradex Systems, Inc. and
Rodman & Renshaw, LLC.
Six public and private companies developing new treatment options for patients with sickle cell disease, including ADVENTRX Pharmaceuticals, Inc., will make presentations. Additionally, clinical researchers investigating approved agents from leading pharmaceutical companies, such as Eisai, Astellas and Lilly, also will present.
Conference attendees will hear from leaders in the sickle cell disease medical and advocacy communities, including:
- Lanetta B. Jordan, MD, MPH, MSPH, Associate Professor at the University of Miami Miller School of Medicine and Chief Medical Officer of the Sickle Cell Disease Association of America, Inc. (SCDAA)
- Kim Smith-Whitley, MD, Medical Director of the Sickle Cell Clinical Program, Clinical Director of the Division of Hematology, and Attending Physician at The Children's Hospital of Philadelphia
- Denis Soulieres, MD, MSc, FRCPC Director of the Molecular Biology and Hematology Laboratory, Oncology & Hematology at the University of Montreal
- Mary M. Hulihan, MPH, Centers for Disease Control (CDC), Division of Blood Disorders of the National Center on Birth Defects and Developmental Disabilities
Question & answer sessions will be moderated by the following healthcare analysts:
- Michael Higgins, Life Sciences Analyst, Brinson Patrick Securities Corporation
- Michael King, Managing Director and Senior Biotechnology Analyst, Rodman & Renshaw, LLC
- Christian Glennie, Healthcare Analyst, Edison Investment Research, Ltd.
"We are excited to present at the Sickle Cell Disease Therapeutics Conference at a time when our product candidate, ANX-188, is poised to commence its Phase 3 clinical study," stated
Brian M. Culley
, Chief Executive Officer of ADVENTRX. "The disease was identified over one hundred years ago, but only one FDA-approved drug is available, and none are available to treat an on-going vaso-occlusive crisis or the underlying ischemia and infarction that reduce the average life expectancy to less than 40 years. Awareness leads to investment, development, and eventually, to new treatments. This conference is an excellent forum to discuss with investors and potential licensing partners the latest advancements for patients suffering with this rare disease."
More information can be found on the conference web site at
or on the advertising flyer for the event at
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate is ANX-188, a rheologic, anti-thrombotic, anti-inflammatory and cytoprotective agent that reduces ischemic tissue injury and end-organ damage by restoring impaired microvascular blood flow, and has potential application in treating a wide range of diseases and conditions, such as complications arising from sickle cell disease. More information can be found on the Company's web site at
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the timing of the Phase 3 study of ANX-188 and the potential for the conference to lead to increased investment in and development of new therapies for patients with sickle cell disease. Among the factors that could cause or contribute to material differences between ADVENTRX's actual results and those indicated from the forward-looking statements are risks and uncertainties inherent in ADVENTRX's business, including, but not limited to: the potential for delays in the commencement of planned clinical studies, including as a result of difficulties or delays in completing manufacturing process development activities and manufacturing clinical trial material or difficulties or delays in obtaining regulatory agreement on clinical study design or meeting applicable regulatory requirements for clinical trial material; the risk of suspension or termination of a clinical study including due to lack of adequate funding; the risk that planned clinical studies are not successful and, even if they are successful, that the FDA could determine they are not sufficient to support an NDA; the potential for ADVENTRX to delay, reduce or discontinue current and/or planned development activities, partner its product candidates at inopportune times or pursue less expensive but higher-risk development paths if it is unable to raise sufficient additional capital as needed; ADVENTRX's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.